Founded in 2012, Wandercraft develops the first robotic exoskeleton providing autonomous, crutch-less, and gradually realistic walk, for SCI, neuromuscular diseases, post-stroke hemiparesis, MS, CP, Parkinson and others. The first commercial Rehab Center version should be proposed to European Physical Medicine and Neurology hospitals and healthcare centers by the end of 2018. FDA approval process will start momentarily.
Wandercraft has developed the worlds first autonomous, self-stabilized dynamically walking exoskeleton. The exo offers disruptive perspectives, to be proven clinically, in rehabilitation, addressing associated diseases and restoring sufficient autonomy in daily life. Wandercraft leverages state of the art robotics and works with advanced medical teams to progress towards:
- More effective inpatient treatments and higher exercise doses in the same timeframe, with a potential to better leverage brain/neural plasticity where relevant, and to better address associated pathologies
- Significant improvement in outpatient quality of life and higher inclusion in patient communities
- Thanks to a unique synergy between restored autonomy and the impact of daily outpatient ambulation, pursuing a continuous treatment in rehabilitation and on associated pathologies, with a near-real time follow up by the patients medical environment
- Lower impact of associated diseases leading to lower health cost for mobility impaired persons
In a few years, a personal version will be issued to increase patient autonomy in their outpatient daily lives while pursuing treatment.
Rehab Center version:
CE marking and commercialization of the first autonomous exo for Rehabilitation and healthcare institutions, enabling medical teams to conduct more effective Inpatient therapies and rehabilitation for walking impaired persons with a relevant condition
Commercialization in Europe end-2018 and FDA in 2019
2018-2020 : Conducting clinical testings, to demonstrate medical benefits on patients with partial or complete SCI, severe neuromuscular diseases, post-stroke hemiparesis, and a fraction of patients with MS, CP, Parkinson related gait disorders.
Development and regulatory approval of the exos Personal version to deliver outpatient autonomy in daily life.
In a later stage, application to elderly will be developed.
Rehabilitation center exo: Wandercraft is currently developing a clinical, commercial and support team to directly address the needs of rehabilitation centers and neurology hospitals in Europe. The team is planned to expand to North America in 2019 and Asia in 2020. The company anticipates to set a pricing model that will offer acquisition, leasing and subscription schemes, to adapt to various healthcare center needs.